Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study

CONCLUSION: Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.PMID:38270124 | DOI:10.1080/08820538.2024.2308808

Source: Seminars in Ophthalmology - January 25, 2024 Category: Opthalmology Authors: Srishti Raksheeth Ramamurthy Umesh Chandra Behera Ritesh Narula SriniVas R Sadda Raja Narayanan Source Type: research